SCHEMBL30748873

SCHEMBL30748873

Clc1ncc(C2CCCO2)c(Nc2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.46
NPC1 O15118 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
SYK P43405 2/20 0.39
GCK P35557 1/20 0.39
KDR P35968 1/20 0.38
TEK Q02763 1/20 0.38
PIN1 Q13526 4/20 0.38
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37
HTT P42858 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748772 0.85 PDE10A (0.44) PDE10ANPC1TP53POLBHPGD
SCHEMBL30748966 0.85 PDE10A (0.44) PDE10ANPC1TP53POLBHPGD
SCHEMBL30748911 0.85 PDE10A (0.44) PDE10ANPC1TP53POLBHPGD
SCHEMBL30748934 0.79 KDR (0.38) SYKKDRTEKPIN1STK17B
SCHEMBL13166189 0.73 STK17A (0.53) TP53KDRTEKPIN1STK17B
SCHEMBL30748907 0.73 KDR (0.47) SYKKDRTEKPIN1STK17B
SCHEMBL30749092 0.73 MEN1 (0.55) KDRTEKPIN1STK17BSTK17A
SCHEMBL30749054 0.70 SMN1; SMN2 (0.51) NPC1RAB9ASYKKDRTEK
SCHEMBL30749000 0.68 KDR (0.42) TP53KDRTEKPIN1STK17B
SCHEMBL30748795 0.68 SYK (0.43) NPC1TP53RAB9ASYKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PDE10A 1621/4885NPC1 1432/4885TP53 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.